Advertisement
U.S. markets open in 58 minutes
S&P Futures
5,753.00 +9.75 (+0.17%) Dow Futures
41,988.00 +32.00 (+0.08%) Nasdaq Futures
20,148.50 +62.50 (+0.31%) Russell 2000 Futures
2,232.00 +0.90 (+0.04%) Crude Oil
71.97 +0.50 (+0.70%) Gold
2,748.70 +2.50 (+0.09%)
Korro Bio, Inc. (KRRO)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 58.16 |
| Open | 55.35 |
| Bid | 59.67 x 100 |
| Ask | 61.14 x 100 |
| Day's Range | 55.10 - 61.36 |
| 52 Week Range | 14.10 - 98.00 |
| Volume | |
| Avg. Volume | 106,242 |
| Market Cap | 559.138M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.19 |
| Earnings Date | Nov 08, 2024 - Nov 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 134.60 |
GlobeNewswireKorro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 -First participant dosing anticipated in first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2 study anticipated in 2026 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Na
Investor's Business DailyKorro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Shares of Korro Bio and Wave Life Sciences diverged Monday after an analyst argued Korro is the better way to play the RNA-editing space.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.